Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR-Reference-Cited by-同舟云学术

Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR

Published:2023-08 Issue:8 Volume:18 Page:1042-1054
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Park Cheol-Kyu,Oh Hyung-Joo,Kim Young-Chul,Kim Yong-Hyub,Ahn Sung-Ja,Jeong Won Gi,Lee Jeong Yeop,Lee Jae Cheol,Choi Chang Min,Ji Wonjun,Song Si Yeol,Choi Juwhan,Lee Sung Yong,Kim Hakyoung,Lee Shin Yup,Park Jongmoo,Yoon Seong Hoon,Joo Ji Hyeon,Oh In-Jae^ORCID

Funder

National Research Foundation of Korea

AstraZeneca Korea

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Beyond concurrent chemoradiation: the emerging role of PD-1/PD-L1 inhibitors in stage III lung cancer;McCall;Clin Cancer,2018

2. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Spigel;J Clin Oncol,2022

3. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

4. Management of stage III non-small-cell lung cancer: ASCO Guideline;Daly;J Clin Oncol,2022

5. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC: results of KINDLE, a multicountry observational study;Jazieh;J Thorac,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer;Scientific Reports;2024-08-23

2. Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia;Meditsinskiy sovet = Medical Council;2024-07-24

3. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data;Cancer Research and Treatment;2024-07-15

4. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR);Radiotherapy and Oncology;2024-07

5. Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;International Journal of Radiation Oncology*Biology*Physics;2024-07